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Objectives: To estimate the prevalence of partly controlled and uncontrolled asthmatic
patients, to evaluate quality of life and healthcare resource consumption.
Methods: Cross-sectional phase followed by a 12-month prospective phase. Asthma Control
Test and the EQ-5D were used.
Results: 2853 adult patients recruited in 56 Hospital Respiratory Units in Italy were evaluated:
64.4% had controlled asthma, 15.8% partly controlled asthma and 19.8% were uncontrolled.
The mean (SD) EQ-5D score was 0.86 (0.17) in controlled, 0.75 (0.20) in partly controlled
and 0.69 (0.23) in uncontrolled patients (p< 0.001 between groups). The number of patients
requiring hospitalization or emergency room visits was lower in controlled (1.8% and 1.6%,
respectively) than in partly controlled (5.1% and 11.5%) and uncontrolled (6.4% and 18.6%).
A combination of an inhaled corticosteroid and a long-acting beta-2 agonist was the reported
therapy by 56.0% of patients, with the rate of controlled asthma and improved quality of life
being higher in patients on extrafine beclomethasone/formoterol compared to budesonide/
formoterol (p< 0.05) and fluticasone/salmeterol (p< 0.05 for quality of life).21 279561; fax: þ39 0521 279592.
oup.com (G. Nicolini).
1 Elsevier Ltd. All rights reserved.
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be detected in a real-life setting in favor of extrafine beclomethasone/formoterol combination.
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Asthma is a worldwide problem affecting more than 300
million people of all ages with a relevant impact on quality
of life and healthcare resources.1 International asthma
guidelines1,2 identify “asthma control” as the objective of
treatment, i.e. achieving and maintaining control of symp-
toms and normal activity levels, maintaining pulmonary
function as close to normal as possible, preventing asthma
exacerbations and asthma mortality and avoiding adverse
effects from asthma medications. The costs of asthma
depend on the individual patient’s level of control and the
extent to which exacerbations are avoided.1 GINA guide-
lines1 define three different levels of asthma control
(controlled, partly controlled or uncontrolled). Ongoing
monitoring is essential in order to assess that control is
reached and maintained for a prolonged period (at least 3
months) before modifying pharmacological treatment.1
In recent years, despite the availability of new pharma-
cological options and new combinations of existing drug
therapies, the rateof suboptimal asthmacontrol is still high. A
population-based survey conducted in 11 European countries
in the frame of the European Community Respiratory Health
Survey II (ECRHS II),3 demonstrated that 32% of patients had
controlled asthma. Recently, a survey conducted in five
Europeancountries indicatedthat50.4%ofasthmaticpatients
were not well controlled4 and this percentage increased to
56.6% in a more recent survey conducted in the same coun-
tries.5 Although these data suggest lack of asthma control in
about half of the patients, an unbiased comparison of data
coming from different studies is difficult due to different
asthma control measures and different data collection
methods adopted. Actually, different questionnaires were
used, not always standardized and validated and data were
collected directly through patient self-administered or web
based questionnaires whereas other studies included either
office-based or hospital-based physician consultations.
Based on this background, and taking into consideration
differences in data collection and in the instruments used to
measure control, our multicenter, observational, cross-
sectional and prospective study on asthma control (PRospec-
tIve Study on asthMA control e PRISMA) was designed to
estimate the level ofdiseasecontrol in Italy inadult asthmatic
patients attending specialist centers. Secondary objectives
were to understand the possible reasons for poor control, to
assess quality of life and economic resources consumption in
asthmatic patients with different levels of asthma control.
Methods
Study objectives
The PRISMA observational study protocol was designed to
include a cross-sectional phase and a 12-month prospectivephase in order to estimate the level of asthma control in
real life and its evolution during a one year follow up. The
main objective of the cross-sectional phase of the study
was to estimate the prevalence of partly controlled and
uncontrolled asthmatic patients in Italy and to describe the
possible reasons for poor control. Further objectives of this
phase were to assess the smoking rate of asthmatic
patients, to collect information on anti-asthma treatments
and their correlation with asthma control, to measure the
amount of healthcare resources used in the 3 months
preceding the first study visit, and to assess the relationship
between level of asthma control as well as treatments
taken at the time of the visit and quality of life. Patients
with controlled asthma were not included in the longitu-
dinal phase of the study.
Study population
Adult smoker and non-smoker asthmatic patients with
a diagnosis of asthma for at least 6 months and attending 56
pneumology centers were enrolled between January and
October 2009. Patients taking part in clinical trials or having
completed a clinical trial in the 12 weeks preceding the
study, those with serious or disabling concomitant diseases,
and pregnant females were excluded.
Data collection and outcome measures
Data were collected by specialists interviewing consecutive
outpatients. The Asthma Control Test (ACT) filled in by
patients was used to assess the level of asthma control in
the 4 weeks preceding the cross-sectional phase consid-
ering an overall score 20 controlled asthma, a score
ranging from 16 to 19 partly controlled asthma, and a score
15 uncontrolled asthma.2,6 Possible reasons for poor
control were described according to doctors’ opinion. When
evaluation of asthma control was related to a specific drug
class therapy, only patients who had been on that therapy
for at least 5 consecutive days in the 3 months before the
visit were included. For the comparison between treat-
ments, only patients who had been on that therapy in the
last 4 weeks were included in the analysis to match with
ACT that evaluates asthma control in the last 4 weeks.
The following additional data were collected in the
cross-sectional phase of the study (first visit): demographic
data, education level (high level including senior secondary
school and college/university graduates), smoking habits,
occupational status, professional exposure to asthma risk
factors/triggers (paint, dust, acids, inhalant gases and
vapors), concomitant diseases, asthma history, health-
related quality of life (HRQOL), past and ongoing asthma
therapies, use of healthcare resources for asthma in the
past 3 months (hospitalizations, emergency department
admissions and medical consultations).
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and an appropriate algorithm8 was used to summarize data
in an overall score ranging from 1 (worse-than-death
health status) to 1 (best health status).
Statistical methods
The sample size of the study was calculated to ensure a rela-
tive error of <30%: a confidence interval for the expected
proportion was calculated using the large sample normal
approximation. The literature shows that 48% of asthmatic
patientshaveuncontrolled orpartly controlledasthma,based
onACT9 and that 5.1%ofpatientshaveoptimal asthmacontrol
after one year of treatment.10 Based on these figures, it was
estimated that a sample of 2750 patients evaluable in the
cross-sectional phase allowed one to observe the 95% confi-
dence interval (CI) proportion of uncontrolled or partly
controlled patients equal to 48% 1.87%. Furthermore, at
least 1270 patients with uncontrolled or partly controlled
asthma in the cross-sectional phase allowed one to observe
the 95% CI proportion of patients reaching asthma control at
the end of the one-year longitudinal phase of the study equal
to 5.1% 1.40 (estimating a 25% drop-out rate and 953
evaluable patients).
Summary statistics (mean, standard deviation, median,
minimum, maximum) were used for continuous variables,
andabsolute and relative frequencydistributionwas used for
categorical data. The Chi square test (or Fisher exact test,
when appropriate) was used to compare categorical vari-
ables among the controlled, partly controlled and uncon-
trolled cohorts of patients, while comparisons of continuous
variables were performed by means of the KruskaleWallis
test. Post-hoc comparisons were performed, when appli-
cable: in such instances, Bonferroni’s correction was
applied. Logistic regression was used to compute odds ratio
(OR), where the dichotomous outcome was the asthma
control (controlled vs partly controlledþ uncontrolled) and
the independent variable was the pharmacological treat-
ment. Multivariate analyses were also performed to assess
the relationship between HRQOL/resource use and asthma
control with the inclusion of additional covariates. Cova-
riates were chosen a priori for all models on the basis of
clinical relevance, which included age, gender (male,
female), educational level (low level/high level), BMI,
asthma risk factors/triggers in the occupational environment
(yes, no), smoking habits (smokers, ex-smokers, non-
smokers), concomitant diseases (yes, no). Multicollinearity
among explanatory variables was investigated to ensure no
correlations between variables. Multiple logistic regression
was used in investigating the association between resource
use (outpatients visits, hospitalization admission, emer-
gency dept. visits) and asthma control, taking into account
the aforementioned covariates. Similarly, multiple linear
regressionmodels were applied for HRQOL (EQ-5D score, EQ-
5D VAS score); in this case variables were standardized.
Significance was set at a two-tailed p value of 0.05.
Ethics
The study was carried out in conformity with Italian rules
on the conduction of observational studies. Patients gavetheir written informed consent prior to study participation.
The study was approved by the Institutional Review Board
in all participating centers.
Results
Characteristics of patients and asthma control
Among 2853 patients enrolled in 56 pneumology centers
across Italy 64.4% were controlled, 15.8% were partly
controlled and 19.8% were uncontrolled (Table 1).
The main reasons for poor control were low adherence
to treatment in 43.3% of patients, exposure to irritants/
triggers in 29.0%, unsatisfactory patientedoctor communi-
cation in 21.2% and inadequate prescribed therapy in 19.9%
of cases. The smoking rate was higher among uncontrolled
(21.2%) than among partly controlled (17.1%) or controlled
patients (14.1%) with an opposite trend in non-smokers and
ex-smokers (77.4% uncontrolled, 84.7% partly controlled
and 85.2% controlled; overall pZ 0.0001).
Patients exposed to asthma risk factors/triggers in the
occupational environmentwere 18.9%,with a higher rate being
observed inuncontrolled (28.1%) compared topartly controlled
(21.5%) and controlled (15.4%) patients (overall p< 0.0001).
High-level education was reported in 52.8% of patients
and was associated with a higher level of asthma control
when compared to low educational level (Table 1).
Approximately half of the patients in employable age were
employed. The distribution of the proportion of controlled
and uncontrolled patients as regards employment was not
different (overall pZ 0.4752).
The following concomitant diseases were more common
in uncontrolled compared to controlled patients, respec-
tively: gastro-oesophageal reflux (29.2% versus 18.6%;
overall pZ 0.0001), sinusitis (21.5% versus 11.3%; overall
p< 0.0001), respiratory infections (7.9% versus 2.5%; over-
all p< 0.0001) and psychological disturbances (4.5% versus
1.0%; overall pZ 0.0003). Male patients were more likely to
be controlled (68.3% of all males) than partly controlled
(14.8%) or uncontrolled (16.9%), when compared to females
(61.9%, 16.4% and 21.6%, respectively; overall pZ 0.0014).
The percentage of obese patients (defined as body mass
index 30) was higher in uncontrolled than controlled or
partly controlled (overall pZ 0.0069) with an opposite
trend in patients with normal weight. The duration of
asthma was longer in uncontrolled than controlled or partly
controlled patients (overall pZ 0.0435).
No other significant difference was observed among
controlled, partly controlled and uncontrolled patients in
the parameters considered (Table 1).
Pharmacologic treatments and asthma control
A total of 83.2% of patients reported taking pharmacologic
asthma therapy for at least 5 consecutive days in the 3
months before the visit (Fig. 1). Fixed combinations
between an inhaled corticosteroid and a long-acting beta-2
agonist (ICS/LABA) were the most used anti-asthma treat-
ments, taken by 56.0% of patients. ICS were used by 11.5%
of patients and leukotriene receptor antagonists (LTRAs) by
24.3%. LABA was used by 22.2% of patients.
Table 1 Patients characteristics.
No. of
evaluable
subjects: 2853
Controlled Partly controlled Uncontrolled Overall
p valuenZ 1836 nZ 451 nZ 566
Age, years, mean (SD) 46 (16) 46 (16) 45 (15) 47 (15) 0.3715
Age categories, n (%) 0.1614
65 years 404 (14.2) 271 (14.8) 53 (11.8) 80 (14.1)
40e64 years 1378 (48.3) 858 (46.7) 231 (51.2) 289 (51.1)
18e39 years 1071 (37.5) 707 (38.5) 167 (37.0) 197 (34.8)
Gender, n (%) 0.0014
Males 1083 (38.0) 740 (40.3) 160 (35.5) 183 (32.3)
Females 1770 (62.0) 1096 (59.7) 291 (64.5) 383 (67.7)
Level of asthma control, n (%) 2853 (100) 1836 (64.4) 451 (15.8) 566 (19.8) NA
Reasons for lack of asthma
control,a n (%)
NA
Poor adherence to therapy 440 (43.3) e 194 (43.0) 246 (43.5)
Continued exposure
to irritants/triggers
295 (29.0) e 124 (27.5) 171 (30.2)
Poor patientedoctor
communication
216 (21.2) e 73 (16.2) 143 (25.3)
Inadequate therapy 202 (19.9) e 86 (19.1) 116 (20.5)
Smoking habits 154 (15.1) e 58 (12.9) 96 (17.0)
Co-morbidities 154 (15.1) e 72 (16.0) 82 (14.5)
Inadequate inhalation technique 63 (6.2) e 26 (5.8) 37 (6.5)
Duration of asthma,
years, mean (SD)
16.9 (13.4) 16.6 (13.6) 16.4 (12.7) 18.2 (13.2) 0.0435
Body mass index categories, n (%) 0.0069
Obese (>30 kg/m2) 507 (17.8) 306 (16.7) 75 (16.6) 126 (22.3)
Overweight (25 and <30 kg/m2) 974 (34.1) 617 (33.6) 162 (35.9) 195 (34.5)
Normal weight (18.5
and <25 kg/m2)
1194 (41.9) 804 (43.8) 188 (41.7) 202 (35.7)
Underweight (<18.5 kg/m2) 75 (2.6) 43 (2.3) 12 (2.7) 20 (3.5)
Not available 103 (3.6) 66 (3.6) 14 (3.1) 23 (4.1)
Smoking habits, n (%) 0.0001
Smokers 455 (16.0) 258 (14.1) 77 (17.1) 120 (21.2)
Non-smokers 1921 (67.3) 1284 (69.6) 287 (63.6) 350 (61.8)
Ex-smokersb 454 (15.9) 280 (15.3) 86 (19.1) 88 (15.6)
Not available 23 (0.8) 14 (0.78) 1 (0.2) 8 (1.4)
Allergies, n (%) 1933 (67.8%) 1248 (68.0%) 317 (70.3%) 368 (65.0%) 0.2675
Concomitant diseases,c n (%) <0.0001
Total 1609 (56.4) 969 (52.8) 287 (63.6) 353 (62.4)
Rhinitis 903 (56.1) 541 (55.8) 164 (57.1) 198 (56.1)
Cardiovascular diseases 396 (24.6) 245 (25.3) 70 (24.4) 81 (23.0)
Gastro-oesophageal reflux 351 (21.8) 180 (18.6) 68 (23.7) 103 (29.2)
Sinusitis 223 (13.9) 109 (11.3) 38 (13.2) 76 (21.5)
Nasal polyposis 118 (7.3) 66 (6.8) 25 (8.7) 27 (7.7)
Type II diabetes 89 (5.5) 50 (5.2) 14 (4.9) 25 (7.1)
Respiratory infections 67 (4.2) 24 (2.5) 15 (5.2) 28 (7.9)
Psychological disturbances 35 (2.2) 10 (1.0) 9 (3.1) 16 (4.5)
Type I diabetes 11 (0.7) 6 (0.6) 2 (0.7) 3 (0.9)
Other diseases 264 (16.4) 156 (16.1) 42 (14.6) 66 (18.7)
Educational level, n (%) 0.0008
Low level 1143 (40.1) 702 (38.2) 177 (39.2) 264 (46.6)
High leveld 1507 (52.8) 1007 (54.8) 240 (53.2) 260 (45.9)
Not available 203 (7.1) 127 (6.9) 34 (7.5) 42 (7.4)
Employment status, n (%) 0.4752
Unemployede 1370 (48.0) 888 (48.4) 226 (50.1) 256 (45.2)
Employed 1383 (48.5) 889 (48.4) 213 (47.2) 281 (49.7)
Not available 100 (3.5) 59 (3.2) 12 (2.7) 29 (5.1)
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Table 1 (continued )
No. of
evaluable
subjects: 2853
Controlled Partly controlled Uncontrolled Overall
p valuenZ 1836 nZ 451 nZ 566
Exposure to asthma risk
factors/triggers in the
occupational environment, n (%)
538 (18.9) 282 (15.4) 97 (21.5) 159 (28.1) <0.0001
NAZ not applicable.
a Patients could have more than one reason.
b Patients who stopped smoking at least one year prior to study start.
c Patients could have more than one concomitant disease.
d High-level education includes senior secondary school and college/university graduates.
e Unemployed patients include students, retirees, unable to work, out-of-work, housewives or other.
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was taken by 48.4% (nZ 1380) of patients, equally
distributed among extrafine beclomethasone/formoterol
(BDP/F) (nZ 454 patients, 32.9% of ICS/LABA fixed
combinations), budesonide/formoterol (BUD/F) (nZ 453,
32.8%) and fluticasone/salmeterol (FP/S) (nZ 473, 34.3%)
(Table 2).
Among patients treated with an ICS/LABA fixed combi-
nation, 72.1% had controlled asthma, whereas 13.7% were
partly controlled and 14.2% were uncontrolled. The
proportion of controlled patients was higher in patients
treated with extrafine BDP/F than in those receiving BUD/F
(Bonferroni’s corrected pZ 0.0320; Fig. 2). The odds ratio
for being controlled was higher in patients treated with
extrafine BDP/F than in those receiving the other two
combinations (pZ 0.012; Table 3).
Therapy with ICS/LABA fixed combination alone was
reported by 782 patients (56.7% of patients on ICS/LABA) of
which 77.9% had controlled asthma, 12.3% partly controlled
and 9.9% uncontrolled asthma. Concomitant anti-asthmatic
treatments were recorded in 43.3% of patients treated withFigure 1 Treatment of asthma in the 3 months before the
cross-sectional phase study visit. Data are percentage of
patients in each category of asthma control reporting therapies
for at least 5 consecutive days in the last 3 months; patients
could have more than one pharmacologic class therapy; ICS:
inhaled corticosteroids; LTRA: leukotriene receptor antago-
nists; CS: corticosteroids.ICS/LABA combinations. The most frequent was LTRAs re-
ported in 28.6% with no differences among the three ICS/
LABA combinations. A concomitant use of as needed short
acting beta-2 agonists was found in 3.3% of patients treated
with ICS/LABA combinations.
The mean [SD] daily dose of ICS in the three ICS/LABA
fixed combinations was lower for extrafine BDP/F as
compared to either BUD/F or FP/S (311.7 [109.5] mg, 590.1
[242.4] mg and 675.3 [342.9] mg, respectively; Bonferroni’s
corrected p< 0.0001; Fig. 3).
Health-related quality of life
The EQ-5D questionnaire and VAS were filled in by 2834
patients. The mean (SD) EQ-5D score was 0.86 (0.17) in
controlled patients, 0.75 (0.20) in partly controlled and
0.69 (0.23) in uncontrolled patients. The mean (SD) of EQ-
5D VAS score was 80.0 (12.7), 68.6 (14.9) and 61.5 (16.3), in
the three subgroups, respectively. Both scores were higher
(i.e. indicative of a better health status) in controlled than
in uncontrolled or partly controlled patients (Bonferroni’s
corrected p< 0.0001), while partly controlled patients had
higher mean scores than uncontrolled patients (Bonferro-
ni’s corrected p< 0.0001). These results were confirmed by
multivariate regression: the adjusted regression coefficient
of control was the highest for both EQ-5D scores (data are
not shown). The mean EQ-5D score was higher in patients
treated with extrafine BDP/F than in those receiving FP/S
(Bonferroni’s corrected pZ 0.018; Fig. 4).
Healthcare resource consumption
Healthcare resource consumption due to asthma in the 3
months preceding the cross-sectional phase visit demon-
strated that 46.5% of patients had an outpatient visit with
either a general practitioner or a specialist, 6.5% had a visit
in an emergency ward and 3.2% of patients were hospital-
ized (Fig. 5). The rate of patients who required admission to
any type of healthcare service was lower in controlled
patients than in uncontrolled and partly controlled (Bon-
ferroni’s corrected p< 0.0001). These results were
confirmed by multivariate logistic regression: the adjusted
OR for control was the highest for all healthcare services
(data not shown).
Table 2 Characteristics of patients treated with ICS/LABA fixed combinations.
No. of evaluable
subjects: 1380
BDP/F extrafine BUD/F FP/S Overall
p valuenZ 454 nZ 453 nZ 473
Age categories, n (%) 0.0028
65 years 242 (17.5) 64 (14.1) 69 (15.2) 109 (23.0)
40e64 years 707 (51.2) 237 (52.2) 237 (52.3) 233 (49.3)
18e39 years 431 (31.2) 153 (33.7) 147 (32.6) 131 (27.7)
Gender, n (%) 0.9379
Males 521 (37.8) 173 (38.1) 168 (37.1) 180 (38.1)
Females 859 (62.3) 281 (61.9) 285 (62.9) 293 (62.0)
FEV1/FVC ratio, mean (SD) 0.76 (0.1) 0.76 (0.1) 0.76 (0.1) 0.75 (0.1) 0.2559
Level of asthma control, n (%) 0.0971
Uncontrolled 196 (14.2) 54 (11.9) 68 (15.0) 74 (15.6)
Partly controlled 189 (13.7) 53 (11.7) 73 (16.1) 63 (13.3)
Controlled 995 (72.1) 347 (76.4) 312 (68.9) 336 (71.0)
Age at diagnosis of asthma, n (%) 0.3005
12 years 189 (13.7) 58 (12.8) 71 (15.7) 60 (12.7)
>12 years 1093 (79.2) 368 (81.1) 348 (76.8) 377 (79.7)
Not available 98 (7.1) 28 (6.2) 34 (7.5) 36 (7.6)
Smoking habits, n (%) 0.1010
Smokers 200 (14.5) 78 (17.2) 69 (15.2) 53 (11.2)
Non-smokers 922 (66.8) 289 (63.7) 305 (67.3) 328 (69.3)
Ex-smokersa 256 (18) 87 (19.2) 78 (17.2) 91 (19.2)
Not available 2 (0.1) 0 (0) 1 (0.2) 1 (0.2)
Concomitant diseases,b n (%)
Rhinitis 461 (56.2) 140 (57.1) 157 (57.1) 164 (54.5) 0.7650
Gastro-oesophageal reflux 180 (21.9) 48 (19.6) 71 (25.8) 61 (20.27) 0.1574
Sinusitis 116 (14.1) 26 (10.6) 48 (17.5) 42 (14.0) 0.0816
Nasal polyposis 74 (9.0) 24 (9.8) 24 (8.7) 26 (8.64) 0.8772
Respiratory infections 27 (3.3) 8 (3.3) 12 (4.7) 7 (2.3) 0.3911
Psychological disturbances 16 (2.0) 5 (2.0) 6 (2.2) 5 (1.7) 0.8961
Inhalant allergies, n (%) 873 (95.3) 274 (94.8) 309 (95.1) 290 (96.0) 0.7605
Concomitant therapies, n (%) 536 (38.8) 170 (37.4) 167 (36.9) 199 (42.1) 0.2024
Hospitalization, n (%) 43 (3.1) 14 (3.1) 16 (3.5) 13 (2.8) 0.7982
Outpatient visits, n (%) 620 (44.9) 192 (42.3) 203 (44.8) 225 (47.6) 0.2324
Access to Emergency Room, n (%) 60 (4.4) 21 (4.6) 22 (4.9) 17 (3.6) 0.6165
ACT scoreZ 25, n (%) 203 (14.7) 73 (16.1) 62 (13.7) 68 (14.4) 0.5773
BDP/FZ beclomethasone/formoterol; BUD/FZ budesonide/formoterol; FP/SZ fluticasone/salmeterol; FEV1Z forced expiratory
volume in 1 s; FVCZ forced vital capacity; ACTZ asthma control test.
a Patients who stopped smoking at least one year prior to study start.
b Patients could have more than one concomitant disease.
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The main results of the cross-sectional phase of the PRISMA
study are indicative of a high proportion of patients with
asthma control in Italy attending specialist centers,
distributed evenly over the country, representative of the
national asthmatic population. An interesting finding of this
study is related to the higher control level and better
quality of life in patients treated with extrafine BDP/F as
compared to BUD/F and FP/S.
Our results confirm previous evidence coming from
a survey conducted in Italy between September 2005 and
January 2006 showing a 64.7% of patients with an ACT score
20.11
A study published in 200812 comparing the level of
asthma control evaluated by patients using a questionnairewith that reported by primary care physicians, highlighted
that physicians estimated a higher level of control
compared to patient-filled questionnaires. Notably, physi-
cians overestimated control, regarding only 42% of patients
as uncontrolled (instead of 59%), although they were more
likely to report plans to alter the regimens of uncontrolled
patients than controlled patients (1.29 versus 0.20 medi-
cation changes per patient) doing so in a fashion consistent
with guideline recommendations. The high level of control
we found in the present study is derived from ACT and EQ-
5D questionnaires that were filled in by patients and,
therefore, it is not likely to be overestimated.
The main reasons for poor control reported in our study
were low adherence to treatment, exposure to irritants/
triggers and unsatisfactory patientedoctor communication,
while inadequate prescribed therapy accounted for poor
Figure 2 Percentage of patients treated with ICS/LABA fixed
combinations with controlled, partly controlled or uncon-
trolled asthma; BDP/FZ beclomethasone/formoterol; BUD/
FZ budesonide/formoterol; FP/SZ fluticasone/salmeterol;
*Bonferroni’s corrected pZ 0.0320 (for controlled vs partly
controlled plus uncontrolled) vs BUD/F.
Figure 3 Mean daily ICS dose in patients treated with ICS/
LABA combinations; BDP/FZ beclomethasone/formoterol;
BUD/FZ budesonide/formoterol; FP/SZ fluticasone/salme-
terol; *Bonferroni’s corrected p< 0.0001 vs BUD/F and FP/S;
xBonferroni’s corrected p< 0.0001 vs FP/S.
Real-life prospective study on asthma control 211asthma control in less than 20% of cases. Moreover, the
population of our study included a significant proportion of
smokers or ex-smokers and, in accordance with literature
reports,5 the data indicate that smoking is a critical factor
associated with an increased risk of poor control13,14 and an
impaired corticosteroid response.15 The evidence that
smoking is correlated with an uncontrolled asthma status
and that healthcare resource consumption, is higher in
uncontrolled than in controlled patients are also in line
with the data of previous surveys conducted in Italy.11,16
There is also confirmatory evidence that various co-
morbid conditions such as rhinosinusitis, gastro-
oesophageal reflux disease, psychological disturbances
and respiratory infections are often observed in asthmatic
patients and may affect asthma control.17 Based on this
perspective, early identification of the clinical and behav-
ioral factors responsible for poor asthma control18 and
interventions during routine outpatient visits for improving
asthma trigger management, are strongly recommended.19
In agreement with previous findings,5,16 asthma control
was worse in women than in men. However, this gender
effect was not confirmed in the international population-
based survey ECRHS II conducted in 11 countries.3 In
contrast with other studies conducted in Europe and in
Italy,5,11 which showed that the probability of being
uncontrolled increases with increased age, our data do not
show a clear correlation between age ranges and level ofTable 3 Odds ratio (OR) for controlled asthma in patients
treated with ICS/LABA fixed combinations.
OR 95% Wald CI p value
BDP/F vs all combinations 1.391 1.075e1.801 0.012
BDP/F vs BUD/F 1.466 1.092e1.967 0.010
BDP/F vs FP/S 1.322 0.985e1774 0.062
BDP/FZ beclomethasone/formoterol; BUD/FZ budesonide/
formoterol; FP/SZ fluticasone/salmeterol; CIZ confidence
interval.asthma control. This finding is in line with the ECRHS II
survey,3 which reported a similar median age in categories
of control. When compared to ECRHS II survey,3 we found
a greater proportion of controlled patients and this
different finding can be due to several reasons. Data re-
ported in the ECRHS II are derived from a sample of asth-
matic patients selected from a general population survey
which were invited to a local chest clinic to undergo
a standardized clinical interview and allergologic and lung
function tests. Asthma control was evaluated with the GINA
guidelines composite measure, including lung function,
whereas in our study asthma control was evaluated with the
ACT that does not include lung function. This is probably
the major difference leading to a lower proportion of
controlled asthma in the ECRHS II study as compared to our
data. Moreover, the sample population that was included in
the ECRHS II study had a higher percentage of smokers (44%
vs 16%), as compared to our study. Finally, the data of
ECHRS II were collected 10 years ago and an improvementFigure 4 Results of EQ-5D score (ranging from 0 to 1) by ICS/
LABA treatment (values are means); BDP/FZ beclometha-
sone/formoterol; BUD/FZ budesonide/formoterol; FP/
SZ fluticasone/salmeterol; *Bonferroni’s corrected pZ 0.018
vs FP/S.
Figure 5 Admission to healthcare services due to asthma in
the 3 months before the first visit (data are rates of patients);
*Bonferroni’s corrected p< 0.001 vs both partly controlled and
uncontrolled patients (post-hoc analysis).
212 L. Allegra et al.in asthma management and control could have occurred
during time.
The analysis of our study data has provided robust
evidence that uncontrolled and partly controlled patients
have more frequent hospitalizations and emergency room
visits and that their quality of life is poorer compared to
controlled patients in agreement with previous find-
ings.9,10,16 Although age, gender, educational level, BMI,
asthma risk factors/triggers in the occupational environ-
ment, smoking habits and concomitant diseases are all
known to be related to both HRQOL and healthcare
resource use, the effect attributable to control, even after
adjustment, was still much higher.
The PRISMA data confirmed that asthma control can be
achieved in a great proportion of patients treated with ICS/
LABA fixed combinations, which were the most commonly
used anti-asthmatic medications. This is in agreement with
recent observational studies which show that ICS/LABA
combinations are the most effective treatment choice.20e22
When looking at the three available different combinations,
differences both in asthma control and quality of life were
detected in favor of the extrafine BDP/F fixed combination.
Notably, patients under treatment with BDP/F extrafine
combination were 40% more likely to be controlled as
compared to BUD/F and FP/S, even if the clinical relevance
of this difference is not clear. Actually, in a large
randomized controlled trial (RCT) comparing BDP/F fixed
combination with the same two drugs administered in
large-particle formulations, a better asthma control was
detected in the BDP/F fixed combination group and was
considered to be related to the lung deposition profile of
BDP/F extrafine formulation.23
The smaller particle size of the extrafine BDP/F combi-
nation, compared to BUD/F and FP/S combinations, both
formulated with larger particles, enables ICS and LABA to
effectively reach and treat both large and small airways,
thus ensuring better treatment of inflammation and
constriction in the entire bronchial tree and therefore
leading to a greater clinical benefit. Indeed, the mass
median aerodynamic diameter of BDP/F extrafine formu-
lation is almost half the size of that in BUD/F and FP/Scombinations.24 Although RCTs are considered the most
rigorous methods to investigate drug efficacy, their design
limits the capacity to provide answers to questions about
more “typical” patient populations and issues found only in
clinical practice. By contrast, observational studies include
larger and more diverse patient populations with common
co-morbidities and can identify clinically important differ-
ences among treatments.25 Asthmatic smokers, usually
excluded from RCTs in asthma, were included in the PRISMA
study. Asthmatic smokers are less responsive to ICS therapy
and several mechanisms are postulated to explain impaired
corticosteroid sensitivity in smokers with asthma.15 Among
these, impaired deposition of drug within the lungs that
may reduce the local availability of ICS at key target cells
within the airways has been suggested.26 It has been
demonstrated that tobacco smokeedrug particle interac-
tions, contributing to the mechanisms of resistance, are
less likely to affect the drug distribution within the lungs in
the case of extrafine formulations,27 suggesting that espe-
cially asthmatic smokers could benefit from extrafine
drugs. In our study improved asthma control and quality of
life was demonstrated for extrafine BDP/F combination
despite the higher proportion of smokers in this group of
patients. The greater benefits on asthma control and
HRQOL with extrafine BDP/F fixed combination detected in
the PRISMA study, that were not shown in previous
comparative RCTs,28,29 could be explained by the above
considerations. Nevertheless, these findings should be
interpreted with caution given the cross-sectional phase of
the study and considering that treatments were started at
variable times before the visit, however with a minimum
time exposure of 1 month. However, no difference was
found in the proportion of patients in terms of concomitant
diseases, allergies or concomitant treatments for asthma
among the three ICS/LABA combinations and the same was
true for smoking status, age at diagnosis and FEV1/FVC
ratio.
Our results are also consistent with the results of a 12-
month randomized trial that evaluated the HRQOL in patients
with asthma who switched from large-particle BDP to extra-
fine BDP. According to this study, clinically important
improvements in asthma-specificquality of lifewereobserved
for the extrafine treated group versus patients treated with
large-particle BDP. According to the authors, improvements in
the small airways with the extrafine formulation may be
detected in the patient’s quality of life but are not captured
by conventional pulmonary function testing.30
This is confirmed by the results of a recent study con-
ducted in an observational real-life context, concluding
that initiating or increasing asthma controller therapy with
an extrafine BDP formulation results in similar or better
asthma control compared with non-extrafine FP, suggesting
that the choice of formulation might result in clinically
meaningful differences.31
Observational studies are limited by possible unmea-
sured or unrecognized confounding factors. We evaluated
the possible role due to propensity to treat patients
differently. Descriptive analyses did not shown any differ-
ence as regards gender, FEV1, smoking habits and co-
morbidities. We also think that recall bias was not a limit
of our study as enrolled patients are affected by asthma
and are sensitive to evoking their symptoms. However,
Real-life prospective study on asthma control 213a strength of this study is that we included a large number
of patients in a specific setting of Italian pneumology
centers, evaluating asthma symptoms by means of a stan-
dardized questionnaire which has been recommended to be
used by international guidelines.1
In conclusion, the cross-sectional phase of the observa-
tional PRISMA study indicated that asthma control can be
achieved in a good proportion of patients and is associated
with better quality of life and reduced health care resource
consumption. ICS/LABA combination is the most common
therapy and differences both in asthma control and in quality
of lifemaybe seen in a real-life setting showingbetter clinical
outcomes in favor of extrafine BDP/F combination with the
advantage of a more efficient ICS dose.Conflict of Interest statement
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